SL Science Holding Ltd
SLBTHealthcare|Biotechnology|US
$0.94
+0.04 (+4.16%)
Financials
Financial Snapshot
Market Cap
$525.7M
Enterprise Value
$524.7M
Revenue (TTM)
—
Net Income (TTM)
—
Cash & Investments
—
Net Cash
—
Free Cash Flow (TTM)
—
Operating CF (TTM)
—
Debt/Equity
0.09
R&D Spending
R&D (2025)
$2.1M
R&D Intensity
94.2%
R&D Growth vs Prior
+2.4%
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $879.0K | $3.4M | $2.2M | |
| R&D Expense | $0.00 | $2.0M | $2.1M | |
| R&D % of Revenue | 0.0% | 60.1% | 94.2% | |
| SG&A | $641.2K | $1.1M | $2.5M |
Income Statement
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $879.0K | $3.4M | $2.2M | |
| Cost of Revenue | $141.0K | $1.4M | $1.4M | |
| Gross Profit | $738.0K | $1.9M | $775.1K | |
| R&D | $0.00 | $2.0M | $2.1M | |
| SG&A | $641.2K | $1.1M | $2.5M | |
| Operating Income | $96.8K | -$1.2M | -$3.8M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $532.9K | -$1.1M | -$3.8M | |
| Net Income | $399.0K | -$1.2M | -$3.8M | |
| EPS (Diluted) | 0.00 | -0.00 | 0.00 | |
| EBITDA | $134.0K | -$1.1M | -$3.7M | |
| Shares Out. (M) | 560.76 | 560.76 | 0.00 |
Balance Sheet
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash & Equivalents | $276.9K | $3.7M | $1.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $3.5M | $5.9M | $1.4M | |
| Total Assets | $4.2M | $5.9M | $2.8M | |
| Total Current Liabilities | $183.0K | $69.2K | $468.5K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $668.1K | $204.9K | $533.3K | |
| Stockholders' Equity | $3.6M | $5.7M | $2.3M | |
| Retained Earnings | $0.00 | -$1.7M | -$5.5M |
Cash Flow Statement
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -$2.5M | $280.2K | -$1.9M | |
| Capital Expenditure | -$183.0K | -$8.0K | -$319.7K | |
| Free Cash Flow | -$2.6M | $272.2K | -$2.2M | |
| Investing Cash Flow | -$183.0K | $123.3K | -$319.7K | |
| Financing Cash Flow | $2.9M | $3.1M | -$879.1K | |
| Issuance of Stock | $0.00 | $7.2M | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | |
| Net Change in Cash | $216.5K | $3.7M | -$2.9M |
Dilution Tracker
Shares Outstanding
561M
5-Year Share Growth
+0.0%
Stock Issuance (2025)
$0.00
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Shares Out. (M) | 560.76 | 560.76 | 0.00 | |
| Change vs Prior % | — | 0.0% | -100.0% | |
| Stock Issuance | $0.00 | $7.2M | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 |
Margins & Profitability
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Gross Margin % | 84.0% | 57.5% | 35.3% | |
| Operating Margin % | 11.0% | -35.6% | -174.6% | |
| Net Margin % | 45.4% | -35.4% | -173.8% | |
| EBITDA Margin % | 15.2% | -34.2% | -170.4% | |
| FCF Margin % | -300.0% | 8.1% | -101.5% | |
| ROE % | 11.2% | -20.8% | -167.2% | |
| ROA % | 9.4% | -20.1% | -135.6% | |
| ROIC % | 1.7% | -20.4% | -153.7% | |
| R&D / Revenue % | 0.0% | 60.1% | 94.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0.0% | 282.7% | -34.7% | |
| Gross Profit | 0.0% | 161.9% | -59.9% | |
| Operating Income | 0.0% | -1335.3% | -220.8% | |
| Net Income | 0.0% | -398.6% | -220.6% | |
| EPS (Diluted) | 0.0% | -400.0% | 100.0% | |
| Operating Cash Flow | 0.0% | 111.4% | -781.7% | |
| Free Cash Flow | 0.0% | 110.3% | -919.1% | |
| R&D Expense | 0.0% | 0.0% | 2.4% | |
| SG&A Expense | 0.0% | 72.9% | 129.5% | |
| Total Assets | 0.0% | 39.8% | -52.5% | |
| Book Value / Share | 0.0% | 60.2% | -100.0% | |
| Debt | 0.0% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | -100.0% |
Valuation
P/E (TTM)At Loss
P/S239.26
P/B0.00
EV/EBITDAAt Loss
EV/Revenue238.78
P/FCFAt Loss
Intrinsic Value Models (per share)
Net Current Assets / Share
$0.00
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| P/E Ratio | 11157.14 | -3719.05 | 0.00 | |
| P/S Ratio | 4982.57 | 1302.04 | 0.00 | |
| P/B Ratio | 1225.44 | 764.71 | 0.00 | |
| EV/EBITDA | 32680.49 | -3808.85 | 0.28 | |
| EV/Revenue | 4982.88 | 1300.94 | -0.48 |